Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2006-04-04
2006-04-04
Martinell, James (Department: 1634)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S023500, C514S04400A
Reexamination Certificate
active
07022828
ABSTRACT:
The present invention relates to nucleic acid molecules, including antisense and enzymatic nucleic acid molecules, such as hammerhead ribozymes, DNAzymes, allozymes, aptamers, decoys and siRNA (RNAi), which modulate the expression or function of IKK genes, such as IKK-gamma, IKK-alpha, or IKK-beta, and PKR genes.
REFERENCES:
patent: 4987071 (1991-01-01), Cech et al.
patent: 5334711 (1994-08-01), Sproat et al.
patent: 5589332 (1996-12-01), Shih et al.
patent: 5624803 (1997-04-01), Noonberg et al.
patent: 5627053 (1997-05-01), Usman et al.
patent: 5631359 (1997-05-01), Chowrira et al.
patent: 5633133 (1997-05-01), Long et al.
patent: 5670633 (1997-09-01), Cook et al.
patent: 5672695 (1997-09-01), Eckstein et al.
patent: 5716824 (1998-02-01), Beigelman et al.
patent: 5741679 (1998-04-01), George et al.
patent: 5792847 (1998-08-01), Buhr et al.
patent: 5801154 (1998-09-01), Baracchini et al.
patent: 5814620 (1998-09-01), Robinson et al.
patent: 5834186 (1998-11-01), George et al.
patent: 5849902 (1998-12-01), Arrow et al.
patent: 5871914 (1999-02-01), Nathan
patent: 5898031 (1999-04-01), Crooke
patent: 5989912 (1999-11-01), Arrow et al.
patent: 6001311 (1999-12-01), Brennan et al.
patent: 6005087 (1999-12-01), Cook et al.
patent: 6107094 (2000-08-01), Crooke
patent: 6159714 (2000-12-01), Usman et al.
patent: 6476205 (2002-11-01), Buhr et al.
patent: 6506559 (2003-01-01), Fire et al.
patent: 2002/0012965 (2002-01-01), Strittmatter
patent: 2359180 (2000-03-01), None
patent: 0360257 (1990-03-01), None
patent: 1325955 (2003-07-01), None
patent: 2000253884 (2000-09-01), None
patent: WO 89/02439 (1989-03-01), None
patent: 90/14090 (1990-11-01), None
patent: WO 91/03162 (1991-03-01), None
patent: WO 92/07065 (1992-04-01), None
patent: WO 93/15187 (1993-08-01), None
patent: WO 93/23057 (1993-11-01), None
patent: WO 93/23569 (1993-11-01), None
patent: 94/01550 (1994-01-01), None
patent: WO 94/02595 (1994-02-01), None
patent: 95/04142 (1995-02-01), None
patent: WO 95/04818 (1995-02-01), None
patent: WO 95/11304 (1995-04-01), None
patent: WO 95/11910 (1995-04-01), None
patent: WO 95/13380 (1995-05-01), None
patent: WO 95/23225 (1995-08-01), None
patent: WO 96/10390 (1996-04-01), None
patent: WO 96/10391 (1996-04-01), None
patent: WO 96/10392 (1996-04-01), None
patent: WO 96/19736 (1996-06-01), None
patent: WO 97/26270 (1997-07-01), None
patent: WO 98/13526 (1998-04-01), None
patent: WO 98/27104 (1998-06-01), None
patent: WO 98/28317 (1998-07-01), None
patent: WO 98/43993 (1998-10-01), None
patent: WO 98/58058 (1998-12-01), None
patent: WO 99/04819 (1999-02-01), None
patent: WO 99/05094 (1999-02-01), None
patent: WO 99/16871 (1999-04-01), None
patent: WO 99/29842 (1999-06-01), None
patent: 99/32619 (1999-07-01), None
patent: 99/49029 (1999-09-01), None
patent: 99/53050 (1999-10-01), None
patent: WO 99/54459 (1999-10-01), None
patent: WO 99/55857 (1999-11-01), None
patent: 99/61631 (1999-12-01), None
patent: WO 00/24931 (2000-05-01), None
patent: WO 00/26226 (2000-05-01), None
patent: 00/44914 (2000-08-01), None
patent: 00/49035 (2000-08-01), None
patent: 00/63364 (2000-10-01), None
patent: 01/36646 (2001-05-01), None
patent: 01/57206 (2001-08-01), None
patent: 01/96584 (2001-12-01), None
patent: 01/097850 (2001-12-01), None
patent: 02/07747 (2002-01-01), None
patent: 02/10378 (2002-02-01), None
patent: 02/22636 (2002-03-01), None
patent: 02/096927 (2002-12-01), None
patent: 03/068797 (2003-08-01), None
patent: 03/070910 (2003-08-01), None
patent: 03/080638 (2003-10-01), None
patent: 04/043977 (2004-05-01), None
patent: 04/072261 (2004-08-01), None
patent: WO 95/06731 (2005-03-01), None
Reynolds et al, Nature Biotechnology 22(3), 326 (2004).
Abramovitz et al., “Catalytic Role of 2'-Hydroxyl Groups Within a Group II Intron Active Site,”Science271:1410-1413 (1996).
Akhtar and Juliano, Cellular Uptake and Intracellular Fate of AntiSense Oligonucleotides,Trends Cell Biol.2:139-144 (1992).
Aldrian-Herrada et al., “A peptide nucleic acid (PNA) is more rapidly internalized in culture neurons when coupled to aretro-inversodelivery peptide. The antisense activity depresses the target mRNA and protein in magnocellular oxytocin neurons,”Nucleic Acids Research26:4910-4916 (1998).
Banerjee and Turner, “The Time Dependence of Chemical Modification Reveals Slow Steps in the Folding of a Group I Ribozyme,”Biochemistry34:6504-6512 (1995).
Bartel and Szostak,“ Isolation of New Ribozymes from a Large Pool of Random Sequences,”Science261:1411-1418 (1993).
Bass, “The short answer,”Nature411:428-429 (2001).
Beaudry and Joyce, “Directed Evolution of an RNA Enzyme,”Science257:635-641 (1992.
Beigelman et al., “Chemical Modification of Hammerhead Ribozymes,”The Journal of Biological Chemistry270:24702-24708 (1995).
Bellas et al., “Inhibition of NF-κB Activity Induces Apoptosis in Murine Hepatocytes,”American Journal of Pathology151:891-896 (1997).
Bellon et al., “Amino-Linked Ribozymes: Post-Synthetic Conjugation of Half-Ribozymes,”Nucleosides&Nucleotides16:951-954 (1997).
Bellon et al., “Post-synthetically Ligated Ribozymes: An Alternative Approach to Iterative Solid Phase Synthesis,”Bioconjugate Chem.8:204-212 (1997).
Berzal-Herranz et al., “Essential nucleotide sequences and secondary structure elements of the hairpin ribozyme,”EBMO J.12:2567-2574 (1993).
Berzal-Herranz et al., “In vitro selection of active hairpin ribozymes by sequential RNA-catalyzed clevage and ligation reactions,”Genes & Development6:129-134 (1992).
Bevilacqua et al., “A Mechanistic Framework for the Second Step of Splicing Catalyzed by theTetrahymenaRibozyme,”Biochemistry35:648-568 (1996).
Blesch, “Delivery of Neurotrophic Factors to Neuronal Targets: Toward Gene Therapy in the CNS,”Drug News&Perspectives13:269-280 (2000).
Boado et al., “Drug Delivery of Antisense Molecules to the Brain for Treatment of Alzheimer's Disease and Cerebral AIDS,”Journal of Pharmaceutical Sciences87:1308-1315 (1998).
Boado, “Antisense drug delivery through the blood-brain barrier,”Advanced Drug Delivery Reviews15:73-107 (1995).
Breaker and Joyce, “Inventing and improving ribozyme function: rational design versus iterative selection methods,”TIBTECH12:268-275 (1994).
Breaker et al., “A DNA enzyme with Mg2-dependent RNA phosphoesterase activity,”Chemistry&Biology2(10):655-660 (1995).
Breaker, “Are engineered proteins getting competition from RNA?”Current Opinion in Biotechnology7:442-448 (1996).
Breaker, “Catalytic DNA: in training and seeking employment,”Nature Biotechnology17:422-423 (1999).
Brennan et al., “Two-Dimensional Parallel Array Technology as a New Approach to Automated Combinatorial Solid-Phase Organic Synthesis,”Biotechnology and Bioengineering(Combinatorial Chemistry) 61:33-45 (1998).
Brody and Gold, “Aptamers as therapeutic and diagnostic agents,”Reviews in Molecular Biotechnology74:5-13 (2000).
Burgin et al., “Chemically Modified Hammerhead Ribozymes with Improved Catalytic Rates,”Biochemistry35:14090-14097 (1996) (vol. No. mistakenly listed as 6).
Burlina et al., “Chemical Engineering of RNase Resistant and Catalytically Active Hammerhead Ribozymes,”Bioorganic&Medicinal Chemistry5:1999-2010 (1997).
Caruthers et al., “Chemical Synthesis of Deoxyoligonucleotides and Deoxyoligonucleotide Analogs,”Methods in Enzymology211:3-19 (1992).
Cech, “Ribozymes and Their Medical Implications,”JAMA260:3030-3034 (1988).
Chartrand et al., “An oligodeoxyribonucleotide that supports catalytic activity in the hammerhead ribozyme domain,”Nucleic Acids Research23(20):4092-4096 (1995).
Chen et al., “Multitarget-Ribozyme Directed to Cleave at up to Nine Highly Conserved HIV 1 env RNA Regions Inhibits HIV-1 Replication-Potential Effectiveness Against Most Presently
Martinell James
McDonnell Boehnen & Hulbert & Berghoff LLP
Sirna Theraputics, Inc.
LandOfFree
siRNA treatment of diseases or conditions related to levels... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with siRNA treatment of diseases or conditions related to levels..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and siRNA treatment of diseases or conditions related to levels... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3563130